Barclays PLC Buys 44,022 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Barclays PLC raised its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 17.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 292,795 shares of the company's stock after purchasing an additional 44,022 shares during the quarter. Barclays PLC owned 0.29% of Intellia Therapeutics worth $6,017,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. ARK Investment Management LLC raised its holdings in shares of Intellia Therapeutics by 5.7% in the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company's stock worth $251,849,000 after purchasing an additional 659,651 shares during the period. State Street Corp increased its position in Intellia Therapeutics by 17.9% in the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after buying an additional 780,754 shares during the last quarter. FMR LLC raised its stake in shares of Intellia Therapeutics by 5.0% in the third quarter. FMR LLC now owns 2,339,522 shares of the company's stock valued at $48,077,000 after buying an additional 111,104 shares during the period. Federated Hermes Inc. lifted its position in shares of Intellia Therapeutics by 19.2% during the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company's stock valued at $51,494,000 after buying an additional 371,189 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock worth $29,648,000 after acquiring an additional 98,865 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares of the company's stock, valued at $893,698.12. This represents a 4.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.20% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on NTLA. Oppenheimer dropped their target price on Intellia Therapeutics from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Monday, November 11th. Citigroup cut their target price on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating for the company in a research note on Friday, October 25th. Royal Bank of Canada reiterated an "outperform" rating and set a $54.00 price target on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Barclays lowered their price target on shares of Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating on the stock in a report on Friday, November 8th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $90.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $54.94.

Intellia Therapeutics Stock Up 0.8 %

Shares of NASDAQ NTLA traded up $0.10 during trading on Friday, reaching $12.18. The company had a trading volume of 3,676,135 shares, compared to its average volume of 1,784,817. Intellia Therapeutics, Inc. has a 12-month low of $11.79 and a 12-month high of $34.87. The business's 50-day moving average is $15.59 and its 200 day moving average is $20.28. The stock has a market cap of $1.24 billion, a PE ratio of -2.24 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analysts' expectations of $8.28 million. During the same quarter in the previous year, the company earned ($1.38) EPS. The company's quarterly revenue was down 24.1% compared to the same quarter last year. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.